Michael Myers Biography and Net Worth

Dr. Myers has more than 38 years of industry experience in the drug delivery and specialty pharmaceutical sectors. He previously served as CEO of Innocoll, Inc. and was responsible for taking that company public in 2014. He has also served as president of the drug delivery division of West Pharmaceutical Services, president of pharmaceutical operations for Fuisz Technologies (Biovail) and has held executive positions in Flamel Technologies and Elan Corporation. Dr. Myers earned his Ph.D. in Chemistry from the University College Cork. Since 2019, Dr. Myers has served as a director of Sonoran Bioscience and Wellesley Pharmaceuticals, each a specialty pharmaceutical company and since 2022 as a director of Cranial Devices, a medical device company.

What is Michael Myers' net worth?: The estimated net worth of Michael Myers is at least $178.01 thousand as of August 31st, 2026. Dr. Myers owns 37,713 shares of Quoin Pharmaceuticals stock worth more than $178,005 as of October 7th. This net worth evaluation does not reflect any other investments that Dr. Myers may own. Learn More about Michael Myers' net worth.
How do I contact Michael Myers?: The corporate mailing address for Dr. Myers and other Quoin Pharmaceuticals executives is 23 Hata'as Street, Kfar Saba, 44425. Quoin Pharmaceuticals can also be reached via phone at +97299741444 and via email at [email protected]. Learn More on Michael Myers' contact information.
Has Michael Myers been buying or selling shares of Quoin Pharmaceuticals?: Michael Myers has not been actively trading shares of Quoin Pharmaceuticals in the last ninety days. Most recently, on Monday, August 31st, Michael Myers bought 20,490 shares of Quoin Pharmaceuticals stock. The stock was acquired at an average cost of $4.88 per share, with a total value of $99,991.20. Following the completion of the transaction, the chief executive officer now directly owns 37,713 shares of the company's stock, valued at $184,039.44. Learn More on Michael Myers' trading history.
Who are Quoin Pharmaceuticals' active insiders?: Quoin Pharmaceuticals' insider roster includes Denise Carter (COO), Anthony Culverwell (Director), Gordon Dunn (CFO), Dennis Langer (Director), and Michael Myers (CEO). Learn More on Quoin Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Quoin Pharmaceuticals?: In the last twelve months, Quoin Pharmaceuticals insiders bought shares 5 times. They purchased a total of 72,522 shares worth more than $408,606.08. The most recent insider tranaction occured on August, 31st when COO Denise P. Carter bought 20,490 shares worth more than $99,991.20. Insiders at Quoin Pharmaceuticals own 11.2% of the company. Learn More about insider trades at Quoin Pharmaceuticals.
Information on this page was last updated on 8/31/2026.

Michael Myers Insider Trading History at Quoin Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/31/2026	Buy	20,490	$4.88	$99,991.20	37,713
9/3/2024	Buy	22	$21.70	$477.40	290

Michael Myers Buying and Selling Activity at Quoin Pharmaceuticals

Quoin Pharmaceuticals Company Overview

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Today's Range

Now: $4.62

$4.51

$4.79

50 Day Range

MA: $5.73

$4.26

$7.87

2 Week Range

Now: $4.62

$3.25

$41.80

Volume

3,610 shs

Average Volume

292,420 shs

Market Capitalization

$9.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56